Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSE:HHH NASDAQ:SRRK NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$28.89+4.2%$19.24$9.57▼$29.34$3.99B12.04 million shs2.62 million shsHHHHoward Hughes$78.78+0.8%$71.99$61.40▼$87.77$4.68B1.21458,377 shs263,595 shsSRRKScholar Rock$31.24-1.1%$35.34$6.76▼$46.98$3.00B0.361.30 million shs1.59 million shsTSHATaysha Gene Therapies$3.25-0.9%$2.77$1.05▼$3.40$886.58M0.982.96 million shs2.52 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+2.06%+7.98%+68.88%+65.65%+27.44%HHHHoward Hughes-1.05%+4.49%+9.79%+11.28%+8.09%SRRKScholar Rock0.00%-4.65%-1.16%-4.33%+271.97%TSHATaysha Gene Therapies+1.23%+15.49%+20.59%+22.85%+43.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$28.89+4.2%$19.24$9.57▼$29.34$3.99B12.04 million shs2.62 million shsHHHHoward Hughes$78.78+0.8%$71.99$61.40▼$87.77$4.68B1.21458,377 shs263,595 shsSRRKScholar Rock$31.24-1.1%$35.34$6.76▼$46.98$3.00B0.361.30 million shs1.59 million shsTSHATaysha Gene Therapies$3.25-0.9%$2.77$1.05▼$3.40$886.58M0.982.96 million shs2.52 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+2.06%+7.98%+68.88%+65.65%+27.44%HHHHoward Hughes-1.05%+4.49%+9.79%+11.28%+8.09%SRRKScholar Rock0.00%-4.65%-1.16%-4.33%+271.97%TSHATaysha Gene Therapies+1.23%+15.49%+20.59%+22.85%+43.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 3.00Buy$43.1451.99% UpsideHHHHoward Hughes 2.50Moderate Buy$83.335.75% UpsideSRRKScholar Rock 3.20Buy$45.7549.39% UpsideTSHATaysha Gene Therapies 3.00Buy$8.29154.55% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, HHH, SRRK, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.008/29/2025HHHHoward HughesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$76.00 ➝ $85.008/22/2025HHHHoward HughesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/21/2025SRRKScholar RockJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/13/2025TSHATaysha Gene TherapiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.50 ➝ $8.008/12/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.008/11/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/8/2025ARWRArrowhead PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $38.008/7/2025SRRKScholar RockBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $45.007/30/2025SRRKScholar RockRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$53.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M1,105.50N/AN/A$1.54 per share18.43HHHHoward Hughes$1.75B2.67$9.67 per share8.15$56.65 per share1.39SRRKScholar RockN/AN/AN/AN/A$3.94 per shareN/ATSHATaysha Gene Therapies$8.10M109.65N/AN/A$0.35 per share9.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)HHHHoward Hughes$200.55M$4.5717.2485.65N/A12.85%10.51%3.15%N/ASRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)TSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest TSHA, HHH, SRRK, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AHHHHoward HughesN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87HHHHoward Hughes1.851.181.18SRRKScholar Rock0.216.336.33TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%HHHHoward Hughes93.83%SRRKScholar Rock91.08%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%HHHHoward Hughes48.00%SRRKScholar Rock13.30%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableHHHHoward Hughes60859.40 million30.89 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableTSHA, HHH, SRRK, and ARWR HeadlinesRecent News About These CompaniesTaysha Gene Therapies (NASDAQ:TSHA) Sets New 52-Week High - Here's WhySeptember 7 at 2:45 AM | americanbankingnews.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.29 Consensus PT from AnalystsSeptember 5, 2025 | americanbankingnews.comTaysha Gene Therapies, Inc. $TSHA Stake Increased by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Purchases 608,200 Shares of Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comNuveen LLC Acquires New Stake in Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comTaysha Gene Therapies, Inc.September 3, 2025 | edition.cnn.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Buy" from BrokeragesSeptember 3, 2025 | marketbeat.comPiper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9August 25, 2025 | msn.comKovitz Investment Group Partners LLC Invests $407,000 in Taysha Gene Therapies, Inc. $TSHAAugust 24, 2025 | marketbeat.comFY2025 Earnings Forecast for TSHA Issued By Chardan CapitalAugust 19, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Forecast for TSHA EarningsAugust 17, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst UpgradeAugust 15, 2025 | marketbeat.comWells Fargo & Company Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00August 15, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00August 14, 2025 | marketbeat.comTaysha Gene Therapies price target raised to $14 from $11 at CanaccordAugust 13, 2025 | msn.com4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...August 13, 2025 | benzinga.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsAugust 13, 2025 | marketbeat.comTaysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...August 13, 2025 | finance.yahoo.comXTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)August 13, 2025 | marketbeat.comTaysha Gene Therapies price target raised to $10 from $9 at ChardanAugust 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, HHH, SRRK, and ARWR Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$28.89 +1.16 (+4.18%) Closing price 04:00 PM EasternExtended Trading$28.40 -0.49 (-1.70%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Howard Hughes NYSE:HHH$78.78 +0.66 (+0.85%) Closing price 03:59 PM EasternExtended Trading$78.50 -0.28 (-0.36%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Scholar Rock NASDAQ:SRRK$31.24 -0.34 (-1.08%) Closing price 04:00 PM EasternExtended Trading$30.77 -0.47 (-1.50%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$3.25 -0.03 (-0.91%) Closing price 04:00 PM EasternExtended Trading$3.21 -0.04 (-1.23%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
